UK Markets open in 6 hrs 50 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
256.79-1.59 (-0.62%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close258.38
Open259.98
Bid257.01 x 1100
Ask260.50 x 800
Day's range253.53 - 260.50
52-week range238.40 - 468.55
Volume947,707
Avg. volume1,072,728
Market cap38.661B
Beta (5Y monthly)0.39
PE ratio (TTM)13.31
EPS (TTM)19.29
Earnings date01 Feb 2022 - 07 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est417.70
  • Motley Fool

    Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

    Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.

  • Bloomberg

    Biogen Stock Plunges 40% Since June on Alzheimer’s Drug Turmoil

    (Bloomberg) -- Biogen Inc. tumbled on Friday as setbacks for its Alzheimer’s disease drug Aduhelm helped erase all the gains the stock had made in 2021.Most Read from BloombergBillionaire Family Feud Puts a Century-Old Business Empire in JeopardyAn Arab City’s Booming Art Scene Is Also a Grab at Soft PowerThe biotech stock has plunged more than 40% after reaching a six-year high in June, when Aduhelm was approved. The decline has wiped out more than $26 billion in Biogen’s market value. On Frida

  • Zacks

    Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More

    Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.